Clinical-stage biotechnology firm Recursion announced the release of an open-source biological dataset, RxRx1, which the company has been building for more than five years. The dataset is composed of ...
Recursion is using AI and machine learning to accelerate drug research and development. The stock has been under pressure amid an uncertain near-term financial outlook. Several clinical updates from ...
Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early ...
SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a Fast Company “Most Innovative Company” and leader in the artificial intelligence for drug discovery movement, today announced it will open-source a ...
On sci-fi TV shows like Star Trek, when a doctor needs to cure a disease, they often ask the computer to simulate complex visualizations or go through databases for potential cures. In real life, ...
Recursion Pharmaceuticals currently has the industry's largest AI supercomputer. It also has partnerships with major drugmakers, but these have yet to yield major wins. Recursion'a lack of clinical ...
One way to think about artificial intelligence, in its modern deep learning form, is as a jigsaw puzzle. You have a picture on the box, and you begin to organize your pieces. "I usually start by ...
REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitors Salt Lake ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results